Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.

MLA

Lombardi, Carlo, et al. “Analysis of the Drop-out Rate in Patients Receiving Mepolizumab for Severe Asthma in Real Life.” Pulmonary Pharmacology & Therapeutics, vol. 54, Feb. 2019, pp. 87–89. EBSCOhost, https://doi.org/10.1016/j.pupt.2018.12.003.

APA

Lombardi, C., Bagnasco, D., Caruso, C., D’Amato, M., Menzella, F., Milanese, M., Senna, G., Canonica, G. W., & Passalacqua, G. (2019). Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology & Therapeutics, 54, 87–89. https://doi.org/10.1016/j.pupt.2018.12.003

Chicago

Lombardi, Carlo, Diego Bagnasco, Cristiano Caruso, Mariella D’Amato, Francesco Menzella, Manlio Milanese, Gianenrico Senna, Giorgio Walter Canonica, and Giovanni Passalacqua. 2019. “Analysis of the Drop-out Rate in Patients Receiving Mepolizumab for Severe Asthma in Real Life.” Pulmonary Pharmacology & Therapeutics 54 (February): 87–89. doi:10.1016/j.pupt.2018.12.003.